Search - tctmd.com

Displaying 41 - 60 of 71

Sort: Relevancy | Date

News Daily News

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

Michael O'Riordan

March 03, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

News Conference News EAS 2020

Just One-Third of European Patients Get to LDL Cholesterol Goals

Michael O'Riordan

October 13, 2020

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

Caitlin E. Cox

September 06, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

More Awareness of Familial Hypercholesterolemia and Severe Dyslipidemia, yet Statin Use Remains Low

Yael L. Maxwell

March 28, 2018

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

3-D Ultrasound Quantifies Plaque Burden in Healthy Middle-Aged Cohort

Michael O'Riordan

July 11, 2017

News Daily News

Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides

Todd Neale

May 26, 2017

News Conference News EAS 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

Yael L. Maxwell

April 26, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

Advertisement

Big Drops in LDL Cholesterol With Inclisiran, but US Clinicians Still Await Drug’s Approval

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Just One-Third of European Patients Get to LDL Cholesterol Goals

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

More Awareness of Familial Hypercholesterolemia and Severe Dyslipidemia, yet Statin Use Remains Low

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

3-D Ultrasound Quantifies Plaque Burden in Healthy Middle-Aged Cohort

Therapies Aimed at New Genetic Target Show Early Promise for Lowering Triglycerides

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content